{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:27:16Z","timestamp":1792794436810,"version":"4.5.0"},"reference-count":93,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2021,5,2]],"date-time":"2021-05-02T00:00:00Z","timestamp":1619913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Agence Nationale de la Recherche for its financial support to the R\u00e9gion Pays de la Loire","id":[{"id":"https:\/\/ror.org\/00rbzpz17","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ion Channels, Science and Therapeutics","award":["ANR-11-LABX-0015"],"award-info":[{"award-number":["ANR-11-LABX-0015"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Coronavirus disease of 2019 (COVID-19) has rapidly become a worldwide pandemic. Many clinical trials have been initiated to fight the disease. Among those, hydroxychloroquine and azithromycin had initially been suggested to improve clinical outcomes. Despite any demonstrated beneficial effects, they are still in use in some countries but have been reported to prolong the QT interval and induce life-threatening arrhythmia. Since a significant proportion of the world population may be treated with such COVID-19 therapies, evaluation of the arrhythmogenic risk of any candidate drug is needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Using the O'Hara-Rudy computer model of human ventricular wedge, we evaluate the arrhythmogenic potential of clinical factors that can further alter repolarization in COVID-19 patients in addition to hydroxychloroquine (HCQ) and azithromycin (AZM) such as tachycardia, hypokalaemia, and subclinical to mild long QT syndrome. Hydroxychloroquine and AZM drugs have little impact on QT duration and do not induce any substrate prone to arrhythmia in COVID-19 patients with normal cardiac repolarization reserve. Nevertheless, in every tested condition in which this reserve is reduced, the model predicts larger electrocardiogram impairments, as with dofetilide. In subclinical conditions, the model suggests that mexiletine limits the deleterious effects of AZM and HCQ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>By studying the HCQ and AZM co-administration case, we show that the easy-to-use O'Hara-Rudy model can be applied to assess the QT-prolongation potential of off-label drugs, beyond HCQ and AZM, in different conditions representative of COVID-19 patients and to evaluate the potential impact of additional drug used to limit the arrhythmogenic risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/europace\/euab043","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T16:23:25Z","timestamp":1613492605000},"page":"1124-1136","source":"Crossref","is-referenced-by-count":10,"title":["Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case"],"prefix":"10.1093","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-5571","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Montnach","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Nantes, CNRS, INSERM, l\u2019institut du thorax, Nantes F-44000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Bar\u00f3","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Nantes, CNRS, INSERM, l\u2019institut du thorax, Nantes F-44000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5057-0998","authenticated-orcid":false,"given":"Flavien","family":"Charpentier","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Nantes, CNRS, INSERM, l\u2019institut du thorax, Nantes F-44000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"De Waard","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Nantes, CNRS, INSERM, l\u2019institut du thorax, Nantes F-44000, France"},{"name":"Laboratory of Excellence, Ion Channels, Science & Therapeutics, Valbonne F-06560, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-5931","authenticated-orcid":false,"given":"Gildas","family":"Loussouarn","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Nantes, CNRS, INSERM, l\u2019institut du thorax, Nantes F-44000, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,2]]},"reference":[{"key":"2021081005505069700_euab043-B1","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"2021081005505069700_euab043-B2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.acvd.2020.03.009","article-title":"COVID-19 in patients with cardiovascular diseases","volume":"113","author":"Hulot","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"2021081005505069700_euab043-B3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"2021081005505069700_euab043-B4","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMc2021225","article-title":"Cardiovascular disease, drug therapy, and mortality in COVID-19","volume":"382","author":"Mehra","year":"2020","journal-title":"N Engl J Med"},{"key":"2021081005505069700_euab043-B5","doi-asserted-by":"crossref","first-page":"e0241955","DOI":"10.1371\/journal.pone.0241955","article-title":"Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review","volume":"15","author":"Izcovich","year":"2020","journal-title":"PLoS One"},{"key":"2021081005505069700_euab043-B6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clinic Rev Allerg Immunol"},{"key":"2021081005505069700_euab043-B7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"2021081005505069700_euab043-B8","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities","volume":"49","author":"Biot","year":"2006","journal-title":"J Med Chem"},{"key":"2021081005505069700_euab043-B9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021081005505069700_euab043-B10","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021081005505069700_euab043-B11","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"2021081005505069700_euab043-B12","doi-asserted-by":"crossref","first-page":"110668","DOI":"10.1016\/j.biopha.2020.110668","article-title":"Insights into antiviral mechanisms of remdesivir, lopinavir\/ritonavir and chloroquine\/hydroxychloroquine affecting the new SARS-CoV-2","volume":"131","author":"Uzunova","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2021081005505069700_euab043-B13","doi-asserted-by":"crossref","first-page":"100747","DOI":"10.1016\/j.nmni.2020.100747","article-title":"Hydroxychloroquine is protective to the heart, not harmful: a systematic review","volume":"37","author":"Prodromos","year":"2020","journal-title":"New Microbes New Infect"},{"key":"2021081005505069700_euab043-B14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12035-020-02093-z","article-title":"Effects of antimalarial drugs on neuroinflammation-potential use for treatment of COVID-19-related neurologic complications","volume":"58","author":"Ong","year":"2021","journal-title":"Mol Neurobiol"},{"key":"2021081005505069700_euab043-B15","first-page":"936","author":"Oldenburg","year":"2020"},{"key":"2021081005505069700_euab043-B16","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.3390\/jcm9092800","article-title":"Impact of Azithromycin and\/or hydroxychloroquine on hospital mortality in COVID-19","volume":"9","author":"Albani","year":"2020","journal-title":"J Clin Med"},{"key":"2021081005505069700_euab043-B17","doi-asserted-by":"crossref","first-page":"554172","DOI":"10.3389\/fphar.2020.554172","article-title":"Systematic review and pharmacological considerations for chloroquine and its analogs in the treatment for COVID-19","volume":"11","author":"Peng","year":"2020","journal-title":"Front Pharmacol"},{"key":"2021081005505069700_euab043-B18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/europace\/euaa216","article-title":"Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings","volume":"22","author":"Gasperetti","year":"2020","journal-title":"EP Europace"},{"key":"2021081005505069700_euab043-B19","first-page":"1","article-title":"Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine","volume":"2016","author":"O\u2019Laughlin","year":"2016","journal-title":"Case Rep Cardiol"},{"key":"2021081005505069700_euab043-B20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/RHU.0b013e31829d5e50","article-title":"Suspected hydroxychloroquine-associated QT-interval prolongation in a patient with systemic lupus erythematosus","volume":"19","author":"Morgan","year":"2013","journal-title":"J Clin Rheumatol"},{"key":"2021081005505069700_euab043-B21","doi-asserted-by":"crossref","first-page":"2264.e5","DOI":"10.1016\/j.ajem.2019.158387","article-title":"Toxicokinetics of hydroxychloroquine following a massive overdose","volume":"37","author":"de Olano","year":"2019","journal-title":"Am J Emerg Med"},{"key":"2021081005505069700_euab043-B22","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/15563650500514558","article-title":"Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia","volume":"44","author":"Chen","year":"2006","journal-title":"Clin Toxicol"},{"key":"2021081005505069700_euab043-B23","doi-asserted-by":"crossref","first-page":"106212","DOI":"10.1016\/j.ijantimicag.2020.106212","article-title":"Frequency of long QT in patients with SARS-CoV-2 infection treated with hydroxychloroquine: a meta-analysis","volume":"56","author":"Oscanoa","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2021081005505069700_euab043-B24","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1086\/508873","article-title":"Antimicrobial-associated QT interval prolongation: pointes of interest","volume":"43","author":"Goldstein","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2021081005505069700_euab043-B25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1540-8159.2007.00887.x","article-title":"Discarding the baby with the bathwater","volume":"30","author":"Kowey","year":"2007","journal-title":"Pacing Clin Electrophysiol"},{"key":"2021081005505069700_euab043-B26","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1111\/j.1540-8159.2007.00912.x","article-title":"Azithromycin-induced torsade de pointes","volume":"30","author":"Huang","year":"2007","journal-title":"Pacing Clin Electrophysiol"},{"key":"2021081005505069700_euab043-B27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40801-016-0062-9","article-title":"Incidence of sustained ventricular tachycardia in patients with prolonged QTc after the administration of azithromycin: a retrospective study","volume":"3","author":"Sears","year":"2016","journal-title":"Drugs Real World Outcomes"},{"key":"2021081005505069700_euab043-B28","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.115.003560","article-title":"Azithromycin causes a novel proarrhythmic syndrome","volume":"10","author":"Yang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2021081005505069700_euab043-B29","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1592\/phco.2006.26.1.147","article-title":"Life-threatening bradyarrhythmia after massive azithromycin overdose","volume":"26","author":"Tilelli","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2021081005505069700_euab043-B30","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10840-007-9124-y","article-title":"Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors","volume":"18","author":"Kezerashvili","year":"2007","journal-title":"J Interv Card Electrophysiol"},{"key":"2021081005505069700_euab043-B31","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"key":"2021081005505069700_euab043-B32","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJMp1302726","article-title":"Cardiovascular risks with azithromycin and other antibacterial drugs","volume":"368","author":"Mosholder","year":"2013","journal-title":"N Engl J Med"},{"key":"2021081005505069700_euab043-B33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/2048872620922784","article-title":"Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol","volume":"9","author":"Naksuk","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2021081005505069700_euab043-B34","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes","volume":"368","author":"Svanstrom","year":"2013","journal-title":"N Engl J Med"},{"key":"2021081005505069700_euab043-B35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/rheumatology\/kel402","article-title":"Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases","volume":"46","author":"Costedoat-Chalumeau","year":"2007","journal-title":"Rheumatology"},{"key":"2021081005505069700_euab043-B36","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.008662","article-title":"The effect of chloroquine, hydroxychloroquine and azithromycin on the corrected QT interval in patients with SARS-CoV-2 infection","volume":"13","author":"Saleh","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2021081005505069700_euab043-B37","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hrthm.2020.05.014","article-title":"QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine\/azithromycin","volume":"17","author":"Chorin","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021081005505069700_euab043-B38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/4312519","article-title":"The outcome of hydroxychloroquine in patients treated for COVID-19: systematic review and meta-analysis","volume":"2020","author":"Ayele Mega","year":"2020","journal-title":"Can Respir J"},{"key":"2021081005505069700_euab043-B39","doi-asserted-by":"crossref","first-page":"e1002061","DOI":"10.1371\/journal.pcbi.1002061","article-title":"Simulation of the undiseased human cardiac ventricular action potential: model formulation and experimental validation","volume":"7","author":"O'Hara","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"2021081005505069700_euab043-B40","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fphys.2012.00360","article-title":"In silico prediction of sex-based differences in human susceptibility to cardiac ventricular tachyarrhythmias","volume":"3","author":"Yang","year":"2012","journal-title":"Front Physiol"},{"key":"2021081005505069700_euab043-B41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.3389\/fphys.2017.00759","article-title":"Computational analysis of the mode of action of disopyramide and quinidine on hERG-linked short QT syndrome in human ventricles","volume":"8","author":"Whittaker","year":"2017","journal-title":"Front Physiol"},{"key":"2021081005505069700_euab043-B42","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1113\/JP276014","article-title":"Long QT syndrome caveolin-3 mutations differentially modulate Kv 4 and Cav 1.2 channels to contribute to action potential prolongation","volume":"597","author":"Tyan","year":"2019","journal-title":"J Physiol"},{"key":"2021081005505069700_euab043-B43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3389\/fphys.2018.01306","article-title":"Modulation of cardiac alternans by altered sarcoplasmic reticulum calcium release: a simulation study","volume":"9","author":"Tomek","year":"2018","journal-title":"Front Physiol"},{"key":"2021081005505069700_euab043-B44","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.003122","article-title":"Dysfunction of the voltage-gated K+ channel beta2 subunit in a familial case of Brugada syndrome","volume":"5","author":"Portero","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2021081005505069700_euab043-B45","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1007\/s40846-017-0257-x","article-title":"Pro-arrhythmogenic effects of the V141M KCNQ1 mutation in short QT syndrome and its potential therapeutic targets: insights from modeling","volume":"37","author":"Lee","year":"2017","journal-title":"J Med Biol Eng"},{"key":"2021081005505069700_euab043-B46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.yjmcc.2015.08.015","article-title":"In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome","volume":"87","author":"Romero","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"2021081005505069700_euab043-B47","doi-asserted-by":"crossref","first-page":"e004628","DOI":"10.1161\/CIRCEP.116.004628","article-title":"Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-a-go-go-related gene) channel-drug binding kinetics and multichannel pharmacology","volume":"10","author":"Li","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2021081005505069700_euab043-B48","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.hrthm.2015.05.027","article-title":"Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: novel electrophysiological insights and therapeutic potential","volume":"12","author":"Capel","year":"2015","journal-title":"Heart Rhythm"},{"key":"2021081005505069700_euab043-B49","doi-asserted-by":"crossref","first-page":"e002345","DOI":"10.1161\/CIRCGEN.118.002345","article-title":"High-throughput functional evaluation of KCNQ1 decrypts variants of unknown significance","volume":"11","author":"Vanoye","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"2021081005505069700_euab043-B50","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1093\/emboj\/16.17.5472","article-title":"Properties of KvLQT1 K+ channel mutations in Romano-ward and Jervell and Lange-Nielsen inherited cardiac arrhythmias","volume":"16","author":"Chouabe","year":"1997","journal-title":"EMBO J"},{"key":"2021081005505069700_euab043-B51","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.hrthm.2019.09.020","article-title":"High-throughput phenotyping of heteromeric human ether-a-go-go-related gene potassium channel variants can discriminate pathogenic from rare benign variants","volume":"17","author":"Ng","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021081005505069700_euab043-B52","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/europace\/eun202","article-title":"The cardiac sodium channel mutation delQKP 1507\u20131509 is associated with the expanding phenotypic spectrum of LQT3, conduction disorder, dilated cardiomyopathy, and high incidence of youth sudden death","volume":"10","author":"Shi","year":"2008","journal-title":"Europace"},{"key":"2021081005505069700_euab043-B53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yjmcc.2018.08.019","article-title":"Arrhythmias precede cardiomyopathy and remodeling of Ca(2+) handling proteins in a novel model of long QT syndrome","volume":"123","author":"Montnach","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"2021081005505069700_euab043-B54","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/BF01963942","article-title":"In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii","volume":"10","author":"Araujo","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2021081005505069700_euab043-B55","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2015.12.033","article-title":"Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3","volume":"67","author":"Mazzanti","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021081005505069700_euab043-B56","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vascn.2016.03.009","article-title":"An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel","volume":"81","author":"Crumb","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2021081005505069700_euab043-B57","doi-asserted-by":"crossref","first-page":"e0220294","DOI":"10.1371\/journal.pone.0220294","article-title":"A modeling and machine learning approach to ECG feature engineering for the detection of ischemia using pseudo-ECG","volume":"14","author":"Ledezma","year":"2019","journal-title":"PLoS One"},{"key":"2021081005505069700_euab043-B58","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/CIRCULATIONAHA.120.048476","article-title":"Association of hydroxychloroquine with QTc interval in patients with COVID-19","volume":"142","author":"Mazzanti","year":"2020","journal-title":"Circulation"},{"key":"2021081005505069700_euab043-B59","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1161\/01.CIR.103.15.2004","article-title":"Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic","volume":"103","author":"Hondeghem","year":"2001","journal-title":"Circulation"},{"key":"2021081005505069700_euab043-B60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1053\/euhj.1998.1094","article-title":"The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens","volume":"19","author":"Elming","year":"1998","journal-title":"Eur Heart J"},{"key":"2021081005505069700_euab043-B61","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/01.RES.41.4.415","article-title":"Action potentials, afterpotentials, and arrhythmias","volume":"41","author":"Cranefield","year":"1977","journal-title":"Circ Res"},{"key":"2021081005505069700_euab043-B62","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/j.1476-5381.2009.00116.x","article-title":"Self-augmentation of the lengthening of repolarization is related to the shape of the cardiac action potential: implications for reverse rate dependency","volume":"156","author":"Virag","year":"2009","journal-title":"Br J Pharmacol"},{"key":"2021081005505069700_euab043-B63","doi-asserted-by":"crossref","first-page":"122","DOI":"10.15420\/aer.2019.8.3","article-title":"Acquired long QT syndrome and electrophysiology of torsade de pointes","volume":"8","author":"El-Sherif","year":"2019","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"2021081005505069700_euab043-B64","author":"Chen"},{"key":"2021081005505069700_euab043-B65","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1540-8167.2006.00698.x","article-title":"L-type calcium current reactivation contributes to arrhythmogenesis associated with action potential triangulation","volume":"18","author":"Guo","year":"2007","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2021081005505069700_euab043-B66","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1540-8167.2007.00726.x","article-title":"Action potential and QT prolongation not sufficient to cause Torsade de Pointes: role of action potential triangulation","volume":"18","author":"Grant","year":"2007","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2021081005505069700_euab043-B67","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19)","volume":"95","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"2021081005505069700_euab043-B68","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1161\/CIRCULATIONAHA.120.047521","article-title":"Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment","volume":"141","author":"Roden","year":"2020","journal-title":"Circulation"},{"key":"2021081005505069700_euab043-B69","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.hrthm.2020.03.024","article-title":"SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes","volume":"17","author":"Wu","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021081005505069700_euab043-B70","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s004390050554","article-title":"Autosomal recessive long-QT syndrome (Jervell Lange-Nielsen syndrome) is genetically heterogeneous","volume":"100","author":"Schulze-Bahr","year":"1997","journal-title":"Hum Genet"},{"key":"2021081005505069700_euab043-B71","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.hrthm.2020.04.045","article-title":"Genetic susceptibility for COVID-19-associated sudden cardiac death in African Americans","volume":"17","author":"Giudicessi","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021081005505069700_euab043-B72","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3389\/fcvm.2020.00085","article-title":"COVID-19 management and arrhythmia: risks and challenges for clinicians treating patients affected by SARS-CoV-2","volume":"7","author":"Carpenter","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2021081005505069700_euab043-B73","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1001\/jamacardio.2020.1834","article-title":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","volume":"5","author":"Mercuro","year":"2020","journal-title":"JAMA Cardiol"},{"key":"2021081005505069700_euab043-B74","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jacep.2015.05.008","article-title":"Mexiletine prevents recurrent torsades de pointes in acquired long QT syndrome refractory to conventional measures","volume":"1","author":"Badri","year":"2015","journal-title":"JACC Clin Electrophysiol"},{"key":"2021081005505069700_euab043-B75","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.hrcr.2020.03.016","article-title":"An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: possible benefits of intravenous lidocaine","volume":"6","author":"Mitra","year":"2020","journal-title":"Heart Rhythm Case Reports"},{"key":"2021081005505069700_euab043-B76","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1126\/science.367.6485.1412","article-title":"Race to find COVID-19 treatments accelerates","volume":"367","author":"Kupferschmidt","year":"2020","journal-title":"Science"},{"key":"2021081005505069700_euab043-B77","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","volume":"26","author":"Chorin","year":"2020","journal-title":"Nat Med"},{"key":"2021081005505069700_euab043-B78","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.hrthm.2020.04.046","article-title":"Chloroquine-induced torsade de pointes in a COVID-19 patient","volume":"17","author":"Szekely","year":"2020","journal-title":"Heart Rhythm"},{"key":"2021081005505069700_euab043-B79","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.tcm.2017.07.010","article-title":"CredibleMeds.org: what does it offer?","volume":"28","author":"Woosley","year":"2018","journal-title":"Trends Cardiovasc Med"},{"key":"2021081005505069700_euab043-B80","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/1574884713666180223123947","article-title":"Drug-induced QT interval prolongation in the intensive care unit","volume":"12","author":"Etchegoyen","year":"2018","journal-title":"CCP"},{"key":"2021081005505069700_euab043-B81","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1113\/JP270526","article-title":"Predicting drug-induced QT prolongation and torsades de pointes","volume":"594","author":"Roden","year":"2016","journal-title":"J Physiol"},{"key":"2021081005505069700_euab043-B82","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/01.CIR.93.3.407","article-title":"Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence","volume":"93","author":"Yang","year":"1996","journal-title":"Circulation"},{"key":"2021081005505069700_euab043-B83","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/01.RES.80.6.782","article-title":"Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells","volume":"80","author":"Yang","year":"1997","journal-title":"Circ Res"},{"key":"2021081005505069700_euab043-B84","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1161\/CIRCULATIONAHA.115.016217","article-title":"Molecular basis of hypokalemia-induced ventricular fibrillation","volume":"132","author":"Pezhouman","year":"2015","journal-title":"Circulation"},{"key":"2021081005505069700_euab043-B85","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1172\/JCI25539","article-title":"Genetics of acquired long QT syndrome","volume":"115","author":"Roden","year":"2005","journal-title":"J Clin Invest"},{"key":"2021081005505069700_euab043-B86","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.jacc.2015.12.063","article-title":"Predicting the unpredictable: drug-induced QT prolongation and torsades de pointes","volume":"67","author":"Schwartz","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2021081005505069700_euab043-B87","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0008-6363(00)00306-0","article-title":"The slow component of the delayed rectifier potassium current in undiseased human ventricular myocytes","volume":"49","author":"Virag","year":"2001","journal-title":"Cardiovasc Res"},{"key":"2021081005505069700_euab043-B88","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.hrthm.2009.08.009","article-title":"Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs alpha-subunit interaction","volume":"6","author":"Biliczki","year":"2009","journal-title":"Heart Rhythm"},{"key":"2021081005505069700_euab043-B89","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yjmcc.2016.09.011","article-title":"Convergence of models of human ventricular myocyte electrophysiology after global optimization to recapitulate clinical long QT phenotypes","volume":"100","author":"Mann","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"2021081005505069700_euab043-B90","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12938-015-0033-5","article-title":"Three-dimensional cardiac computational modelling: methods, features and applications","volume":"14","author":"Lopez-Perez","year":"2015","journal-title":"Biomed Eng Online"},{"key":"2021081005505069700_euab043-B91","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.hrthm.2010.10.048","article-title":"Counterpoint: m cells do not have a functional role in the ventricular myocardium of the intact heart","volume":"8","author":"Janse","year":"2011","journal-title":"Heart Rhythm"},{"key":"2021081005505069700_euab043-B92","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/HCO.0b013e328333d3d6","article-title":"Electrical remodeling in the failing heart","volume":"25","author":"Aiba","year":"2010","journal-title":"Curr Opin Cardiol"},{"key":"2021081005505069700_euab043-B93","doi-asserted-by":"crossref","first-page":"587709","DOI":"10.3389\/fphys.2020.587709","article-title":"Beta-adrenergic receptor stimulation modulates the cellular proarrhythmic effects of chloroquine and azithromycin","volume":"11","author":"Sutanto","year":"2020","journal-title":"Front Physiol"}],"container-title":["EP Europace"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/23\/7\/1124\/39622799\/euab043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/europace\/article-pdf\/23\/7\/1124\/39622799\/euab043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T01:53:26Z","timestamp":1628560406000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/23\/7\/1124\/6261974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,2]]},"references-count":93,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,5,2]]},"published-print":{"date-parts":[[2021,7,18]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euab043","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,7,1]]},"published":{"date-parts":[[2021,5,2]]}}}